Overview

Immune Tolerance Study With Aldurazyme® (Laronidase)

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if treatment with an antigen-specific immunosuppressive can decrease or stop an antibody response to laronidase (Aldurazyme®) during enzyme replacement therapy with laronidase in severe Mucopolysaccharidosis I (MPS I) participants.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Collaborator:
BioMarin/Genzyme LLC
Treatments:
Azathioprine
Cyclosporine
Cyclosporins